ImmunityBio Announces Over 24 Months Median Duration of Complete Remission, with 100% NMIBC CIS Patient Survival, Setting a New ‘Magnitude of Benefit’ in Patients with BCG Unresponsive Bladder Cancer

Results confirm prolonged sustained complete response, with 71% of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) having a complete remission with a median duration of response of 24.1 months By contrast, historical...

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI with Median Overall Survival of 6.3 Months in Patients with Third-Line Disease, More than Doubling Historical Survival

Data show that ImmunityBio’s combination immunotherapy, Nant Cancer Vaccine, is potentially effective in pancreatic cancer where very few treatment options exist Nant Cancer Vaccine therapy more than doubles median overall survival (OS) versus historical OS in...